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This study is one of the few to characterize immunohistochemically the distribution and localization of Receptor-Associated
Protein(RAP)inhumanautopsybrain.Theresultsshowprominentcorticalneuronallocalization.RAPisclearlyidentiﬁedinlarge
neuronal dendritic/axonal processes. RAP is expressed in both large pyramidal and smaller interneurons. Occasional, much less
frequent RAP is detectable in glial cells in white matter, which appear to be predominantly astrocytic. Although RAP is detectable
immunohistochemically in Alzheimer’s disease autopsy brain, the level of expression appears signiﬁcantly reduced relative to age-
matched control brains. These results suggest, at the immunohistochemical level, that there is a reduction of RAP protein in
Alzheimer’s disease brain (cortex). In terms of Alzheimer’s disease pathophysiology, a reduction of neuronal RAP could then lead
to reduced membrane expression of LRP, since RAP has also been shown to be an LRP antagonist.
1.Introduction
Receptor-associated protein (RAP) is a 39-kilo Dalton pro-
tein which is part of the large family of small GTPase
proteins. It has also been shown to be a molecular
chaperone for a number of receptor proteins, including
low density lipoprotein receptor-related protein (LRP) [1–
4]. LRP is a membrane protein which binds to amyloid
precursor protein (APP), allowing its uptake and cellular
internalization and subsequent processing to beta amyloid
peptides [5, 6]. Alzheimer’s disease is characterized by the
excessiveaccumulationsofbetaamyloidpeptidewithinbrain
regions, including areas of cortex. Beta amyloid is a peptide
fragment derived from the larger precursor protein APP. The
pathophysiology underlying the vast majority of Alzheimer’s
disease, that is, the sporadic nonfamilial cases, remains
unknown. Given that RAP can modulate LRP function; it
potentially could play a role in the transmembrane intra-
cellular handling of APP and subsequent conversion to beta
amyloid peptide. This clearly could be signiﬁcant in terms
of contributing to AD pathogenesis by aﬀecting the beta
amyloid peptide burden. RAP can also modulate the ligand
binding activity of LRP through antagonism. As part of
our ongoing studies examining mechanisms of beta amyloid
clearancefromhumanbrainandourpreviousstudieshaving
examined LRP, as well as receptor for advanced glycosalation
end (RAGE) products alterations in Alzheimer’s brain, we
decided to examine the immunohistochemical expression
of RAP in both normal human and Alzheimer’s cortex.
There are only a few existing studies examining RAP in
human brain of any type. One study has shown RAP to
be present in cerebellar Purkinje cells [7]. Another study
has observed a reduction of RAP in Alzheimer’s relative to
normative brains using biochemical means [8–10]. There are
a number of lines of evidence suggesting a reduction of beta
amyloidpeptideclearancecontributingtotheaccumulations
which occur in Alzheimer’s disease [11]. Therefore, any
factor which alters or modulates beta amyloid uptake and
neuronal processing, or microvascular clearance through
modulations of other receptor proteins such as LRP, could2 Pathology Research International
Table 1: Case descriptions.
Condition Case Gender Age Braak and Braak stage Cerad level
Nondemented comparison cases
1F 5 8 0 N / A
2F 7 2 0 N / A
3F 5 7 0 N / A
4M 7 5 0 N / A
5M 6 9 0 N / A
6M 4 5 0 N / A
7F 4 3 0 N / A
8M 4 1 0 N / A
9M 7 1 0 N / A
10 F 74 0 N/A
Alzheimer cases
1 M 88 6 High
2 F 75 6 High
3 M 60 5/6 High
4 F 74 6 High
5 F 83 5/6 High
6 M 74 3/4 High
7 F 84 5/6 High
8 M 84 5/6 Mod
9 M 83 1/2 High
10 M 74 3/4 High
be of signiﬁcance. This study reports on our ﬁndings with
immunohistochemical patterns of expression in Alzheimer’s
and a normative comparison group of normal brain cortices.
2.MaterialsandMethods
This study examined a cohort of 20 brains derived from
the neuropathology autopsy service of Hamilton Health Sci-
ences, McMaster University. Ten brains represented cases of
Alzheimer’s disease (AD), all with clinical dementia sympto-
mology and neuropathologic conﬁrmed typical Alzheimer’s
pathology, without signiﬁcant confounding variables or
other pathologic processes. In addition, there was a cohort of
ten normative control brains (NM) free of signiﬁcant cere-
brovascular neuropathology or neurodegenerative process,
withoutsigniﬁcantcognitive ordementiasymptomology. All
brainsunderwentadetailedneuropathologicexaminationby
one of us (J.Provias, Neuropathologist), as well as CERAD
[12] and Braak and Braak staging [13]. Standardized and
comparable areas of superior temporal (ST) and occipital
cortex (COC) were further examined from each brain
and underwent immunohistochemical staining for receptor-
associated protein (RAP). This was in addition to the stan-
dard neuropathologic workup utilizing immunohistochem-
istry for beta amyloid and tau. RAP immunohistochemistry
was performed using a mouse monoclonal antibody at a
working dilution of 1/200 (Bio Design International clone
7F1, Saco Me.). The distribution of RAP immunopositivity
and the cellular characteristics were characterized in all cases
and a semiquantitative assessment of the intensity of staining
wasdeterminedusinga0–4+scale.Ineachcaseweexamined
10 contiguous ×400 magniﬁcation ﬁelds from the sampled
cortices. The mean intensity values were determined based
on the observations from the 10 ﬁelds per cortical sample.
3. Results
Table 1 summarizes the case descriptions. This study was
meant to examine the expression of RAP in Alzheimer’s
disease cortex by looking at the temporal and occipital
regions. It was not meant to look at expression in early
versus late disease or in relation to disease progression.
Therefore the selection of the AD cases includes brains
with lower as well as higher Braak and Braak stages. Future
studies employing a greater number of cases of each Braak
and Braak stage will examine this latter point. Our results
indicate that RAP can be detected immunohistochemically
in autopsy human brain (Figure 1). There is strong cortical
expressionofRAPinavarietyofcelltypes,bothneuronsand
glia. Neurons show particularly intense immunopositivity
with both larger pyramidal and smaller neurons being
immunoreactive. The staining pattern was predominantly
cytoplasmic, in some cases with a granular pattern present,
consistent with endoplasmic reticular localization. Some
neurons show prominent staining of neuritic processes.
Subcortical white matter showed more restricted positivity
with some focal positivity in glial cells. Further positivity was
seen in some capillaries within endothelial cells. Within the
Alzheimer’s disease brains, the cortical positivity was present
as in the normative, although less intense. Mean qualitative
neuronal observation values, when observed on a scale of 0–
4, was 2.9 and 2.6 in the superior temporal and calcarinePathology Research International 3
100× 400×
600× 200×
AB
CD
(a) ImmunopositiveRAPincorticalcellsofanormativebrain.Noteprominentneuronalpositivity.Highpower
magniﬁcations show granular neuronal cytoplasmic positivity and areas of dendritic positivity (B, C). Note also
positivity in glial cells (arrows, D).
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(b) A representative panel showing positive microvessels (capillaries) with RAP positivity endothelial cells from
a normative brain.
200× 100×
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(c) A panel showing the marked reduction in intensity of immunopositivity for RAP in Alzheimer’s disease
cortex, note weak staining of cortical neurons and absent staining of microvessels (see arrows).
Figure 1: RAP immunohistochemistry in normal human cortex and Alzheimer’s disease.
cortices, respectively, in normative brains, and 1.9 and 1.5
in the superior temporal and calcarine cortices, respectively,
in Alzheimer brains (Figure 2). No signiﬁcant diﬀerences
were observed between ST and COC values within each
condition. However, signiﬁcant diﬀerences (P<. 001) were
observed when comparing NM and AD conditions within
comparable areas of the ST and COC areas. Of note, the
pattern through Alzheimer’s cortex was a diﬀuse cellular
neuronal pattern without localization to senile plaques. The
results indicate a reduced intensity of neuronal staining4 Pathology Research International
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Figure 2: RAP immunmopositivity intensity-qualitative results.
This bar graph summarizes the mean neuronal RAP density
qualitative observations, and includes SEM values and P-values
comparing ST and COC means between the Normative and AD
conditions.
through the Alzheimer’s disease cortex, both temporal and
occipital, although with a similar qualitative cellular pattern
of positivity. There was also a suggestion of reduced intensity
of capillary vascular RAP positivity within the AD brains.
Signiﬁcant changes in glial RAP staining were not observed.
4. Discussion
This study is one of the very few which has examined RAP
expression in human cortex. This study has demonstrated
the immunohistochemical detection of RAP in both normal
and Alzheimer’s disease human cortex. There is greater
expression in cortex than white matter, with the vast major-
ity of cortical neurons showing strong immunopositivity
irrespective of their neuronal size or morphology. RAP
does not appear limited to neurons however, with detection
being present in glial cells, particularly in subcortical white
matter, some of which are clearly oligodendroglial cells. RAP
is a 39-kilo Dalton protein which is thought to function
as a molecular chaperone for other receptor proteins, in
particular the LDL receptor protein family [1–4, 14]. The
presence of RAP in cortical neurons would be consistent
with its function as a modulator of low density lipoprotein
receptor-related protein expression through its molecular
chaperonefunctions.LRPisimportantasamajormembrane
receptor,allowingthebindinganduptakeofamyloidprecur-
sor protein, which in turn undergoes proteolytic cleavage to
beta amyloid fragments [5, 6]. These beta amyloid fragments
are one of the key pathologic abnormalities of Alzheimer’s
disease brain with excessive accumulation underlying the
senile plaque pathology and thought by many to be a key
initial causative event in the subsequent pathophysiologic
chain of alterations occurring in Alzheimer’s disease brain
[5,6].Therefore,neuronalRAPbymodulatingLRPfunction
and the uptake and processing of APP into beta amyloid
could play a role in the overall modulation of the beta
amyloid peptide burden of normal and Alzheimer’s disease
brain[10,15–17].HoweverthedistributionofRAPindicates
a complexity as not only neuronal but also vascular and
glial compartments contain RAP and could contribute
to pathophysiologic alterations in Alzheimer’s. The most
striking change observed in these 10 cases was however
the reduction in neuronal RAP with a suggestion of lesser
reduction in vascular RAP. Future studies will have to look at
these latter 2 compartments in more detail particularly as to
how they may interact with neuronal RAP.
Though a preliminary qualitative study, this study sug-
gests that in Alzheimer’s disease cortex there is a reduction of
RAP as indicated by reduced immunostaining. This change
was seen in both temporal and occipital regions suggesting
it may be widespread. This quantitative downregulation
of RAP protein, in turn, could modify the LRP/APP/beta
amyloid processing. A reduction of RAP in AD brain could
reducetheLRPstabilityandmembranelocalizationbyvirtue
of its loss of chaperone function; this could be a protective
or adaptive response in an attempt to reduce APP to beta
amyloid processing. There is some evidence that RAP can
also antagonize the LRP receptor [1–4, 10]; this would
suggest that reduced neuronal RAP could lead to increased
LRP receptor activity and APP internalization and possibly
subsequent processing to beta amyloid peptide. There was
a suggestion of some reduction of intensity of capillary
endothelial RAP immunopositivity within the AD brains.
However this was not as marked as the neuronal alterations
seen.
These results should be correlated in the future with
biochemical analysis to conﬁrm RAP reductions within
Alzheimer’s brain. They point towards the signiﬁcance of
alterations of modulating factors of the APP/beta amyloid
processing pathway, potentially contributing to AD patho-
genesis.
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